Case-Based Update on Hypoparathyroidism - Online
Case-Based Update on Hypoparathyroidism - Online
The online enduring activity Case-Based Update on Hypoparathyroidism was originally presented at Clinical Endocrinology Update 2016 in Seattle, Washington on September 9, 2016.
This activity is supported by an educational grant from Shire.
This continuing medical education activity should be of substantial interest to endocrinologists, endocrine fellows, and healthcare professionals who treat patients with bone disorders.
Upon completion of this educational activity, learners will be better able to:
- Describe the pathophysiology and differential diagnosis of hypoparathyroidism
- Identify the clinical manifestations of hypoparathyroidism
- Understand the mechanism and utility of new and emerging therapies in the management of hypoparathyroidism
- Develop safe and effective treatment plans for patients with hypoparathyroidism
Steven Harris, MD, FACP – Program Director
Clinical Professor of Medicine
University of California, San Francisco Medical Center
San Francisco, CA
Lynn Kohlmeier, MD
Endocrinology and Metabolic Bone
Spokane Internal Medicine
Spokane Osteoporosis, Director
Washington Osteoporosis Coalition
Susan Ott, MD
Professor of Medicine
Metabolism, Endocrinology and Nutrition
University of Washington
Department of Medicine
Nelson Watts, MD
The faculty, committee members, and staff who are in position to control the content of this activity are required to disclose to the Endocrine Society and to learners any relevant financial relationship(s) of the individual or spouse/partner that have occurred within the last 12 months with any commercial interest(s) whose products or services are related to the CME content. Financial relationships are defined by remuneration in any amount from the commercial interest(s) in the form of grants; research support; consulting fees; salary; ownership interest (e.g., stocks, stock options, or ownership interest excluding diversified mutual funds); honoraria or other payments for participation in speakers' bureaus, advisory boards, or boards of directors; or other financial benefits. The intent of this disclosure is not to prevent CME planners with relevant financial relationships from planning or delivery of content, but rather to provide learners with information that allows them to make their own judgments of whether these financial relationships may have influenced the educational activity with regard to exposition or conclusion.
The Endocrine Society has reviewed all disclosures and resolved or managed all identified conflicts of interest, as applicable.
The faculty reported the following relevant financial relationship(s) during the content development process for this activity:
Steven Harris, MD, FACP (Chair): Speaker, Shire
Susan M Ott, MD: Speaker, Amgen
Nelson Watts, MD: Research Support, Shire; Consultant, Shire; Speaker, Shire
The faculty reported no relevant financial relationships: Lynn Kohlmeier, MD
The following SPC member who planned and reviewed content for this activity reported the following financial relationships: E Michael Lewiecki, MD: Advisory Board, Amgen, Merck, Eli Lilly, Radius Health, Shire, and Alexion; Speaker, Shire; Research Grant Support, Amgen, Eli Lilly, Merck
Endocrine Society staff associated with the development of content for this activity reported no relevant financial relationships.
DISCLAIMERS USE OF PROFESSIONAL JUDGMENT:
The educational content in this activity relates to basic principles of diagnosis and therapy and does not substitute for individual patient assessment based on the health care provider’s examination of the patient and consideration of laboratory data and other factors unique to the patient. Standards in medicine change as new data become available.
DRUGS AND DOSAGES:
When prescribing medications, the physician is advised to check the product information sheet accompanying each drug to verify conditions of use and to identify any changes in drug dosage schedule or contraindications.
POLICY ON UNLABELED/OFF-LABEL USE
The Endocrine Society has determined that disclosure of unlabeled/off-label or investigational use of commercial product(s) is informative for audiences and therefore requires this information to be disclosed to the learners at the beginning of the presentation. Uses of specific therapeutic agents, devices, and other products discussed in this educational activity may not be the same as those indicated in product labeling approved by the Food and Drug Administration (FDA). The Endocrine Society requires that any discussions of such “off-label” use be based on scientific research that conforms to generally accepted standards of experimental design, data collection, and data analysis. Before recommending or prescribing any therapeutic agent or device, learners should review the complete prescribing information, including indications, contraindications, warnings, precautions, and adverse events. PRIVACY AND
The Endocrine Society will record learner’s personal information as provided on CME evaluations to allow for issuance and tracking of CME certificates. The Endocrine Society may also track aggregate responses to questions in activities and evaluations and use these data to inform the ongoing evaluation and improvement of its CME program. No individual performance data or any other personal information collected from evaluations will be shared with third parties.
ACKNOWLEDGMENT OF COMMERCIAL SUPPORT
This educational activity is supported by an independent medical educational grant from Shire
The Endocrine Society is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The Endocrine Society has achieved Accreditation with Commendation.
The Endocrine Society designates this live activity for a maximum of 2.00 AMA PRA Category 1 Credits. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
- 2.00 AMA PRA Category 1 Credits™
- 2.00 CME Certificate of Participation